Endo International (Endo International) Additional Paid-In Capital : $8,981 Mil(As of Dec. 2023)

View and export this data going back to 2000. Start your Free Trial

What is Endo International Additional Paid-In Capital?

Endo International's quarterly additional paid-in capital stayed the same from Jun. 2023 ($8,981 Mil) to Sep. 2023 ($8,981 Mil) and stayed the same from Sep. 2023 ($8,981 Mil) to Dec. 2023 ($8,981 Mil).

Endo International's annual additional paid-in capital increased from Dec. 2021 ($8,954 Mil) to Dec. 2022 ($8,969 Mil) and increased from Dec. 2022 ($8,969 Mil) to Dec. 2023 ($8,981 Mil).

Endo International Additional Paid-In Capital Historical Data

The historical data trend for Endo International's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Endo International Additional Paid-In Capital Chart

Endo International Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Additional Paid-In Capital

Get a 7-Day Free Trial

8,904.69

8,938.01

8,953.91

8,969.32

8,980.56

Endo International Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Additional Paid-In Capital	Get a 7-Day Free Trial															8,969.32	8,980.56	8,980.56	8,980.56	8,980.56

Endo International Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Endo International Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Endo International's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Endo International (Endo International) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Endo International PLC (OTCPK:ENDPQ) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

EO7:Germany

Address

Simmonscourt Road, Ballsbridge, First Floor, Minerva House, Dublin, IRL, 4

Website

https://www.endo.com

Endo International PLC is a specialty pharmaceutical company with a considerable presence in pain management, urology, orthopedics, endocrinology, bariatrics, and others. It operates in four segments: Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals, and International Pharmaceuticals. The company generates maximum revenue from the Branded Pharmaceuticals segment. Some of its products include XIAFLEX, SUPPRELIN, PERCOCET, TESTOPEL, VASOSTRICT, ADRENALIN, and APLISOL.

Executives

James Patrick Tursi	officer: Executive VP, Global R&D	106 ASHLEY COURT, MOORESTOWN NJ 08057
Frank B. Raciti	officer: VP, Controller and CAO	C/O ENDO HEALTH SOLUTIONS INC., 1400 ATWATER DRIVE, MALVERN PA 19355
Shane Cooke	director	TREASURY BUILDING LOWER GRAND CANAL ST., DUBLIN 2 L2 00000
William P Montague	director
Jennifer M Chao	director	7 PURITAN WOODS ROAD, RYE NY 10580
George Apostol	officer: EVP, Head of Global R&D	C/O ENDO INTERNATIONAL PLC, FIRST FL, MINERVA HOUSE, SIMMONSCOURT RD, BALLSBRIDGE, DUBLIN 4 L2 00000
Mary Christine Smith	director	3658 50TH AVE NE, SEATTLE WA 98105
Mark T. Bradley	officer: EVP, Chief Financial Officer	C/O ENDO INTERNATIONAL PLC, FIRST FL, MINERVA HOUSE, SIMMONSCOURT RD, BALLSBRIDGE, DUBLIN L2 00000
Mark G Barberio	director	19 WIK STREET, WILLIAMSVILLE NY 14221
Jack D. Boyle	officer: SVP, Interim Controller	C/O ENDO INTERNATIONAL PLC, FIRST FL, MINERVA HOUSE, SIMMONSCOURT RD, BALLSBRIDGE, DUBLIN L2 00000
Roger H Kimmel	director	LATHAM & WATKINS, 885 THIRD AVENUE, NEW YORK NY 10022
Domenico Ciarico	officer: EVP & Chief Commercial Officer	C/O ENDO INTERNATIONAL PLC, FIRST FL, MINERVA HOUSE, SIMMONSCOURT RD, BALLSBRIDGE, DUBLIN L2 00000
Rahul Garella	officer: EVP, Intl Pharmaceuticals	C/O ENDO INTERNATIONAL PLC, FIRST FL, MINERVA HOUSE, SIMMONSCOURT RD, BALLSBRIDGE, DUBLIN L2 00000
Nancy J Hutson	director	64 MONTAUK AVENUE, STONINGTON CT 06378
Carrie Ann Nichol	officer: VP, Controller & CAO	927 GRANDVIEW DRIVE, EXTON PA 19341